HomeDiscoveryPublicationsPublications 2011

Publications 2011



Summarizing probe intensities of affymetrix GeneChip 3′ expression array taking into account day-to-day variability
Magni P, Simeone A, Healy S, Isacchi A, Bosotti R
IEEE/ACM Trans Comput Biol Bioinform
(2011), 8(5), 1425-30

A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors
Massard C, Soria JC, Anthoney DA, Proctor A, Scaburri A, Pacciarini MA, Laffranchi B, Pellizzoni C, Kroemer G, Armand JP, Balheda R, Twelves CJ
Cell Cycle
(2011), 10(6), 963-970

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib
Steeghs N, Mathijssen RH, Wessels JA, de Graan AJ, van der Straaten T, Mariani M, Laffranchi B, Comis S, de Jonge MJ, Gelderblom H, Guchelaar HJ
Invest New Drugs
(2011), 29(5), 953-62

Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro
Balabanov S, Gontarewicz A, Keller G, Raddrizzani L, Braig M, Bosotti R, Moll J, Jost E, Barett C, Rohe I, Bokemeyer C, Holyoake TL, Brümmendorf TH
PLoS One
(2011), 6(4), e19164

Mechanisms of Action of a Dual Cdc7/Cdk9 Kinase Inhibitor against Quiescent and Proliferating CLL Cells
Natoni A, Murillo LS, Kliszczak AE, Catherwood MA, Montagnoli A, Samali A, O’Dwyer M, Santocanale C
Mol Cancer Ther
(2011) 10(9), 1624-1634

Structural basis for CARM1 inhibition by indole and pyrazole inhibitors
Sack JS, Thieffine S, Bandiera T, Fasolini M, Duke GJ, Jayaraman L, Kish KF, Klei HE, Purandare AV, Rosettani P, Troiani S, Xie D, Bertrand JA.
Biochem J.
(2011) 436(2), 331-339

Identification of candidate substrates for poly(ADP-ribose) polymerase-2 (PARP2) in the absence of DNA damage using high-density protein microarrays
Troiani S, Lupi R, Perego R, Re Depaolini S, Thieffine S, Bosotti R, Rusconi L.
(2011) 278(19), 3676-3687

Targeting the DFG-in kinase conformation: a new trend emerging from a patent analysis
Angiolini M
Future Med Chem.
(2011) 3(3), 309-337

NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor
Beria I, Bossi RT, Brasca MG, Caruso M, Ceccarelli W, Fachin G, Fasolini M, Forte B, Fiorentini F, Pesenti E, Pezzetta D, Posteri H, Scolaro A, Re Depaolini S, Valsasina B
Bioorg Med Chem Lett.
(2011) 21(10), 2969-2974.

Targeting aneuploid cancer cells
Colombo R, Moll J
Expert Opin Ther Targets
(2011) 15(5), 595-608

From polymer to small organic molecules: a tight relationship between radical chemistry and solid-phase organic synthesis
Mirizzi D, Pulici M
(2011) 16(4), 3252-3314

Synthesis and SAR of new pyrazolo[4,3-h]quinazoline-3-carboxamide derivatives as potent and selective MPS1 kinase inhibitors
Caldarelli M, Angiolini M, Disingrini T, Donati D, Guanci M, Nuvoloni S, Posteri H, Quartieri F, Silvagni M, Colombo R
Bioorg Med Chem Lett.
(2011) 21(15), 4507-4511